Evaluation of Effectiveness of Different Dosage of Neostigmine in Combination with Metoclopramide, on Gastric Residual Volume
Phase 2
Recruiting
- Conditions
- Gastric residual volume.
- Registration Number
- IRCT20170903036041N1
- Lead Sponsor
- Vice chancellery for research Iran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 165
Inclusion Criteria
Enteral nutrition feeding
After three hours from the last gavage gastric residual volume =50%
Age 18-60
Exclusion Criteria
Diabetes mellitus disease
Atrioventricular block
Heart rate <60
Systolic blood pressure <90
Within 10 days Gastrointestinal surgery
Clinical signs of Gastrointestinal obstruction
Bronchospasm or Asthma history
In 24 hours administration of Prokinetic drugs
Sensitivity to Metoclopramide or Neostigmine
Kidney failure or Creatinine >2 milligram/deciliter
Hypokalemia
Concomitant medication with Cyclosporine
Digoxin and Monoamine Oxidase inhibitors
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gastric residual volume. Timepoint: three hours after the completion of the infusion. Method of measurement: Cc.
- Secondary Outcome Measures
Name Time Method Age. Timepoint: At the time of entering the study. Method of measurement: Chronological age.;Blood pressure. Timepoint: Recorded during the measurement of the gastric remaining volume. Method of measurement: mmHg (millimeters of mercury).;Respiratory rate. Timepoint: Recorded during the measurement of the gastric remaining volume. Method of measurement: The number of movements indicative of inspiration and expiration per unit time.;Heart rate. Timepoint: Recorded during the measurement of the Gastric remaining volume. Method of measurement: Number of contractions of the heart per minute (bpm).